ADVAIR HFA 45/21, 115/21, 230/21 (fluticasone propionate 45 mcg, 115 mcg, 230 mcg and salmeterol 21 mcg) Inhalation Aerosol Please review this safety information. Below you can learn about the risks and side effects of ADVAIR. This, however, is not all of the safety information, and it does not replace talking to your healthcare professional about your medical condition or treatment. Important Note. The following information is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. Detailed drug Information for Advair Diskus 100/50. Includes common brand names, drug descriptions, warnings, side effects and dosing information. This demonstration is intended to complement the Patient Information for ADVAIR DISKUS. For full instructions on how to use ADVAIR DISKUS, and other important information, please see the complete Prescribing Information, including Patient Information and Instructions for Use for ADVAIR DISKUS. IMPORTANT SAFETY INFORMATION FOR ADVAIR 250/50 and INCRUSE IMPORTANT SAFETY INFORMATION FOR ADVAIR DISKUS 250/50. ADVAIR DISKUS contains salmeterol, the same medicine found in SEREVENT DISKUS (salmeterol xinafoate inhalation powder). Long-acting beta-agonists (LABAs): The FDA has recommended LABAs be used ONLY in conjunction with inhaled steroids in asthma. Generic Name. Photo Advair Diskus 250/50 is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Advair Diskus 250/50 is also indicated to reduce exacerbations of COPD in patients with a 2 inhalations inhaled orally twice daily, morning and evening, approximately 12 hours apart, of either ADVAIR HFA 45/21 (45 mcg fluticasone and 21 mcg salmeterol per inhalation), Advair HFA 115/21 (115 mcg fluticasone and 21 mcg salmeterol per inhalation), or Advair HFA 230/21 (230 mcg fluticasone and 21 mcg salmeterol per inhalation). Pharmacy and Therapeutics Committee-approved Therapeutic Interchanges Therapeutic Interchange Revision Date Alpha Blockers 08/11 Alpha Reductase Inhibitors 05/16.